Company profile
Adaptimmune Therapeutics plc (ADAP)
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
AD01 | Transaction MzUxMjU4MDQzMGFkaXF6a2N4
Published 25 Mar 2026 19:25
AD01 | Transaction MzUxMjU4MDIzMGFkaXF6a2N4
Published 25 Mar 2026 19:19
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Jan 2014 to 31 Dec 2016
Adaptimmune has developed the adoptive transfer of T cells genetically engineered to express optimised affinity T cell Receptors (TCR) that target cancer peptide antigens. This approach generates potent anti-tumour immunity. This disruptive therapy has the potential to treat late stage diseases, such as Triple Negative Breast Cancer, for which there is a ...
